Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 4:41 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,412 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Parkinson's Disease Clear all
Completed Phase 2 Interventional Results available

Safety of Urate Elevation in Parkinson's Disease

NCT00833690
View directory record Official record
Conditions
Parkinson Disease
Interventions
Placebo, inosine
Drug
Lead sponsor
The Parkinson Study Group
Network
Eligibility
30 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Los Angeles, California • Manchester, Connecticut • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2014 · Synced Nov 1, 2026, 4:41 AM EST
Terminated No phase listed Observational Accepts healthy volunteers

Characteristics of Parkinson s Disease Associated With the LRRK-2 Gene Mutation

NCT00467090
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Nov 1, 2026, 4:41 AM EST
Enrolling by invitation No phase listed Observational

An Observational Study of Patients With Moderate Parkinson's Disease

NCT05779475
View directory record Official record
Conditions
Parkinson Disease
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
50 Years to 68 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
3
States / cities
Irvine, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Nov 1, 2026, 4:41 AM EST
Completed Not applicable Interventional

BUrst vs. Spaced Physical Therapy for Parkinson's Disease: The BUS PT Timing Trial

NCT05180747
View directory record Official record
Conditions
Parkinson Disease
Interventions
Frequency of physical therapy sessions
Other
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Nov 1, 2026, 4:41 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease

NCT05894343
View directory record Official record
Conditions
Parkinson's Disease
Interventions
AAV-GAD
Genetic
Lead sponsor
MeiraGTx, LLC
Industry
Eligibility
25 Years to 86 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
New Haven, Connecticut • West Bloomfield, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 1, 2026, 4:41 AM EST
Completed Phase 3 Interventional

Timing of Levodopa Treatment in Parkinson's Disease

NCT00004733
View directory record Official record
Conditions
Parkinson's Disease
Interventions
levodopa
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
30 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 1, 2026, 4:41 AM EST
Completed Not applicable Interventional

Parkinson's Improvement Activated by Hula Understanding

NCT06543810
View directory record Official record
Conditions
Parkinson Disease
Interventions
Hula for Parkinson's
Other
Lead sponsor
University of Hawaii
Other
Eligibility
25 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 1, 2026, 4:41 AM EST
Completed Phase 3 Interventional

Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.

NCT00036218
View directory record Official record
Conditions
Parkinson Disease
Interventions
sumanirole, ropinirole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
93
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Carmichael, California + 81 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2006 · Synced Nov 1, 2026, 4:41 AM EST
Recruiting Not applicable Interventional

Accelerated TMS for Freezing of Gait in Parkinson's Disease

NCT06982638
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
TMS+ Gait training
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
50 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Nov 1, 2026, 4:41 AM EST
Completed No phase listed Observational

Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography.

NCT02132052
View directory record Official record
Conditions
Essential Tremor, Multiple System Atrophy, Corticobasal Degeneration, Supranuclear Palsy, Progressive, Parkinson Disease
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Nov 1, 2026, 4:41 AM EST
Completed Phase 1Phase 2 Interventional

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease

NCT03257046
View directory record Official record
Conditions
Parkinson Disease
Interventions
ITI-214, Placebo
Drug · Other
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Nov 1, 2026, 4:41 AM EST
Active, not recruiting Not applicable Interventional

Mobility in Daily Life and Falls in Parkinson's Disease: Potential for Rehabilitation

NCT04897256
View directory record Official record
Conditions
Parkinson Disease
Interventions
TURN-IT exercise program
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
55 Years to 85 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Nov 1, 2026, 4:41 AM EST
Not listed Phase 1 Interventional

A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214

NCT02579473
View directory record Official record
Conditions
Parkinson's Disease
Interventions
SER-214
Drug
Lead sponsor
Serina Therapeutics
Industry
Eligibility
40 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Birmingham, Alabama • Hallandale, Florida • Augusta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Nov 1, 2026, 4:41 AM EST
Completed Phase 4 Interventional Results available

RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)

NCT00998660
View directory record Official record
Conditions
Parkinson's Disease, Essential Tremor, Dystonia
Interventions
Activa RC
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
7 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Cincinnati, Ohio • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Nov 1, 2026, 4:41 AM EST
Completed No phase listed Observational

Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center

NCT01465360
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Vascular Dementia, Fronto-temporal Dementia, Primary Progressive Aphasia, Parkinson' Disease Dementia, Mixed Dementia
Interventions
Not listed
Lead sponsor
Exonhit
Industry
Eligibility
21 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
3
States / cities
Las Vegas, Nevada • Cleveland, Ohio • Lakewood, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 6, 2012 · Synced Nov 1, 2026, 4:41 AM EST
Completed Phase 2 Interventional

12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa

NCT00456586
View directory record Official record
Conditions
Parkinson's Disease
Interventions
KW-6002 (istradefylline)
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
30 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Nov 1, 2026, 4:41 AM EST
Completed Phase 1 Interventional

A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease

NCT04295642
View directory record Official record
Conditions
Parkinson Disease
Interventions
CVL-751
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
45 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Long Beach, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Nov 1, 2026, 4:41 AM EST
Not listed Phase 2 Interventional

Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease

NCT01560754
View directory record Official record
Conditions
Parkinson's Disease
Interventions
nicotine transdermal patch
Drug
Lead sponsor
James BOYD MD
Other
Eligibility
30 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Los Angeles, California • Sunnyvale, California • Honolulu, Hawaii + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2015 · Synced Nov 1, 2026, 4:41 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Study of the Effects of Glucose on Cognition in Healthy Young and Elderly People and Parkinson's Disease Patients

NCT00004451
View directory record Official record
Conditions
Parkinson Disease
Interventions
Glucose
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1998
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 1, 2005 · Synced Nov 1, 2026, 4:41 AM EST
Completed Phase 2 Interventional Results available

Nilotinib in Parkinson's Disease

NCT03205488
View directory record Official record
Conditions
Parkinson Disease
Interventions
Cohort 1:Nilotinib Oral Capsules (150mg or 300mg), Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1), Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 79 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
24
States / cities
Birmingham, Alabama • Sun City, Arizona • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Nov 1, 2026, 4:41 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease

NCT03611569
View directory record Official record
Conditions
Healthy, Parkinson Disease
Interventions
Lu AF82422, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
4
States / cities
Glendale, California • Hollywood, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Nov 1, 2026, 4:41 AM EST
Completed Not applicable Interventional

Priming Through Timing. Using Opposing Strategies to Enhance Motor Learning for Individuals With Parkinson's Disease

NCT03660605
View directory record Official record
Conditions
Parkinson Disease
Interventions
Rhythmic Auditory Stimulation
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Nov 1, 2026, 4:41 AM EST
Recruiting Not applicable Interventional

At-home taVNS for Neurorehabilitation in Parkinson's Disease

NCT07536022
View directory record Official record
Conditions
Parkinson's Disease
Interventions
transcutaneous auricular nerve stimulation
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
40 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Nov 1, 2026, 4:41 AM EST
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

NCT00368108
View directory record Official record
Conditions
Parkinson's Disease
Interventions
2 mg perampanel, 4 mg perampanel, placebo comparator
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
30 Years and older
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
99
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Nov 1, 2026, 4:41 AM EST